Lung Cancer Perspective

 
 
  • Two Decades of Lung Cancer Advances   On the 20th anniversary of Medscape, Dr Mark Kris highlights major changes in lung cancer treatment during that time and suggests future directions for the field.
  • Early-Phase Research Comes to Fruition in Lung Cancer   ASCO 2015 will feature a number of clinical trials confirming early results for immune checkpoint inhibitors, targeted therapies, and a second-generation cisplatin analogue, according to Dr Mark Kris.
  • Treating Progression of EGFR-Mutant Lung Cancer   When it comes to progression in a patient with EGFR-mutant lung cancer, it's by no means one-size-fits-all. Dr Mark Kris discusses treatment options.
  • Genomic Sequencing: Refining Lung Cancer Staging Dr Jack West comments on a very provocative proof of principle demonstrating the effect next-generation sequencing may have on tumor staging.
  • Targeting ROS1-Positive Lung Cancers   The approval of crizotinib stands to have an outsize impact for a small but significant population of patients with ROS1-positive lung cancer.
  • Recent Advances in Squamous Cell Lung Cancer   Squamous cell tumors represent 20% of all lung cancers. Dr Mark Kris discusses new approaches to the diagnosis and treatment of these tumors, including nivolumab and ramucirumab.
  • HER2 Dependency in Lung Cancers   What have we learned about treating HER2-mutant lung cancers? Dr Mark Kris explores this new topic in the field of thoracic oncology.
  • RTOG 0617 Trial: With Chest Radiation, More Is Not Better Dr Jack West discusses two studies that challenge the prevailing presumption that in cancer treatment 'more must be better' and that underscore the value of clinical trials that refute these presumptions.
  • IMPRESS Trial: Navigating the Switch to Chemo From a TKI   Dr Mark Kris discusses the details of the IMPRESS trial, which assessed the effect of discontinuing gefitinib in patients with EGFR-mutant lung cancer who have developed resistance to the drug.
  • Special Report: Lung Cancer Screening Experts from a number of specialties discuss the recent decision by CMS to pay for lung cancer screening with low-dose CT.
  • EGFR Mutant Lung Cancer: Lessons From ASPIRATION and IMPRESS   Dr Mark Kris discusses the switch from first- to second-line therapy for EGFR mutant lung cancers in light of two studies presented at the most recent ESMO meeting.
  • CT Screening for Lung Cancer: A Study in Cost-Effectiveness   Dr Andrew Shorr encourages his colleagues to consider new research that analyzes the cost-effectiveness of CT screening patients at risk for lung cancer.
  • The Case for Neoadjuvant Therapy in Lung Cancer   Dr Mark Kris discusses the benefits of neoadjuvant therapy for patients with locally advanced lung cancers, from treating micrometastases to assessing response to therapy.
  • Lung Cancer: To Screen or Not to Screen   The Centers for Medicare & Medicaid Services will reimburse counseling on the pros and cons of lung cancer screening with high-risk patients. So what should we tell them?
  • Four Years After NLST, Lung Screening Uptake 'Way Too Slow'   Dr Mark Kris reviews recent developments in lung cancer screening and calls on the oncology community to recommend screening to all eligible candidates.
  • Does SBRT Revolutionize Metastatic NSCLC? Dr Jack West argues that an encouraging new study of stereotactic body radiation therapy should not necessarily change practice.
  • CMS Proviso on Lung Cancer Screening: Good or Bad? Potential barriers or appropriate guardrails? Dr Jack West comments on the recent CMS decision to cover lung cancer screening -- provided that certain conditions are met.
  • The Year in Lung Cancer: CT Screening, More Targeted Therapy Lung cancer experts highlight the most important developments and practice-changing clinical trials of 2014.
  • Use 'TKI as Long as You Can' in NSCLC   Two studies presented at ESMO 2014 clarify the sequence of therapies after disease progression in EGFR-mutated non-small cell lung cancer.
  • The Value of Multiplex Genotyping for Lung Cancer   Dr Mark Kris discusses the development of the Lung Cancer Mutation Consortium, a group of lung cancer specialists who sought to prove the value of multiplex genotyping.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.